Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Mediscience Stepping Up Athlete Recruitments as CMRs
August 21, 2012
- ARB Prescription Rate Affected by Doctors’ Evaluations of MRs: M3 Survey
August 21, 2012
- Generic Actos Launched in US; Takeda Grants AG to Teva, Ranbaxy
August 21, 2012
- Astellas to Build New Building to Boost Production Capacity of Investigational Anticancer Drug Substances
August 21, 2012
- DSP to Set Up Cancer Institute Led by CEO of Its US Subsidiary BBI
August 21, 2012
- Synagis IM Liquid Injection Solution Approved: Abbott Japan
August 20, 2012
- Pfizer Terminates Development of AD Treatment Bapineuzumab
August 20, 2012
- RIBOMIC Acquired Patent for Analgesic Agent Containing Aptamer
August 20, 2012
- “Sense of Achievement” Motivates MRs; Brach Managers to Be Blamed for Miscommunications: Survey of Managers
August 20, 2012
- OncoTherapy Confirms Safety of OCV-C01 for Pancreatic Cancer in PIII Trial
August 17, 2012
- Mizuho Forecasts Sales Increases and Falling Profits in FY2012 for 9 Major Domestic Pharmaceutical Manufacturers
August 17, 2012
- Bonac Confirms Safety of RNAi Agents for Pulmonary Fibrosis in Animal Studies
August 17, 2012
- “Character” Tops List of Traits Doctors Require of MRs: MREAC Survey
August 17, 2012
- Higher Dose of Methotrexate Approved: Pfizer
August 17, 2012
- Teijin Pharma Obtains Approval for Bonalon Jelly
August 16, 2012
- Humira Can Be Used for RA Patients without Treatment History: Abbott, Eisai
August 16, 2012
- Eisai’s US Subsidiary Morphotek Opens New Antibody Production Plant
August 16, 2012
- AZ, Pfizer Enter into Agreement for OTC Nexium, Also Eyeing OTC Versions of Other AZ Products
August 16, 2012
- Additional Indication of Pancreatic Neuroendocrine Tumors Approved for Sutent: Pfizer
August 16, 2012
- Symbicort Approved for COPD: Astellas, AZ
August 16, 2012
ページ
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…